Furthermore, FEN1 inhibitors not only hinder NB cell proliferation but also enhance the chemotherapeutic effectiveness of cisplatin, paving the way for novel strategies in the clinical management of high-risk NB patients. This evidence concerns the gene FEN1 and neuroblastoma.